Headlines

Bristol Myers (BMY) said studies demonstrated iza-bren achieved statistically significant in overall survival and progression-free survival in heavily pretreated, unresectable locally advanced or metastatic triple-negative breast cancer

Newsquawk Staff ·

Bristol Myers (BMY) said studies demonstrated iza-bren achieved statistically significant in overall survival and progression-free survival in heavily pretreated, unresectable locally advanced or metastatic triple-negative breast cancer.

Related headlines